OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Strosberg on Cabozantinib vs Placebo in Patients With Advanced GI NETs

January 29th 2025

Jonathan R. Strosberg, MD, discusses the evaluation of cabozantinib vs placebo in patients with advanced gastrointestinal neuroendocrine tumors.

Dr DeAngelo on the FDA Approval of Obe-Cel in R/R B-Cell Precursor ALL

January 29th 2025

Daniel DeAngelo, MD, PhD, discusses data supporting the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

Dr Ip on Real-World Data Informing CAR T-Cell Therapy Selection in LBCL

January 29th 2025

Andrew Ip, MD, discusses the importance of making informed clinical decisions when selecting CAR T-cell therapy in older vs younger patients with LBCL.

Dr Zakharia on Long-Term Benefit With Nivolumab Plus Ipilimumab in ccRCC

January 28th 2025

Yousef Zakharia, MD, discusses the long-term benefits of nivolumab plus ipilimumab according to risk status in clear cell renal cell carcinoma.

Dr Shaukat on the PREEMPT CRC Blood-Based Assay for Average-Risk CRC

January 28th 2025

Aasma Shaukat, MD, MPH, discusses the sensitivity of the PREEMPT CRC blood-based assay in detecting colorectal cancer for patients at average risk.

Dr Shah on the Effect of IVIG on Infection Risk in R/R Multiple Myeloma

January 28th 2025

Mansi R. Shah, MD, highlights the data on the effects of IVIG on infections in patients with relapsed/refractory multiple myeloma treated with teclistamab.

Dr Oberstein on Data for Pamrevlumab Plus Nab-Paclitaxel/Gemcitabine in PDAC

January 28th 2025

Paul E. Oberstein, MD, discusses the efficacy and safety of pamrevlumab plus chemotherapy in first- and second-line PDAC.

Dr Dizman on the Rationale of Evaluating CBM588 in Metastatic RCC

January 27th 2025

Nazli Dizman, MD, explains the rationale for evaluating the impact of CBM588 on the gut microbiome in patients with metastatic RCC.

Dr Horinouchi on Safety Data for Adjuvant Alectinib in ALK+ NSCLC

January 27th 2025

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Dr Akkooi on Pathologic Review Discrepancies and Overtreatment Risks in Metastatic Melanoma

January 27th 2025

Alexander C.J. Van Akkooi, MD, PhD, FRACS, discusses how discrepancies in local and central pathologic review can expose patients to potential toxicities associated with overtreatment for metastatic melanoma.

Dr Hinchcliff on the Addition of Dostarlimab to Chemotherapy in Advanced/Recurrent Endometrial Cancer

January 27th 2025

Emily Hinchcliff, MD, MPH, discusses the addition of dostarlimab to standard-of-care chemotherapy in patients with advanced/recurrent endometrial cancer.

Dr Garcia-Manero on Dual IRAK4/FLT3 Inhibition With Emavusertib in MDS and AML

January 27th 2025

Guillermo Garcia-Manero, MD, discusses the rationale for investigating the dual inhibition of IRAK4 and FLT3 with emavusertib in MDS and AML

Dr Kopetz on the Phase 3 BREAKWATER Trial in Frontline Metastatic CRC

January 25th 2025

Scott Kopetz, MD, PhD, FACP, discusses findings from the phase 3 BREAKWATER study of frontline encorafenib plus cetuximab with or without chemotherapy in BRAF V600E–mutated metastatic CRC.

Dr Teng on the Phase 2 CARES-005 Study of TACE Plus Camrelizumab and Rivoceranib in Unresectable HCC

January 25th 2025

Gao-Jun Teng, MD, discusses findings from the phase 2 CARES-005 trial of TACE plus camrelizumab and rivoceranib vs TACE alone in patients with unresectable HCC.

Dr Hinchcliff on the Evolving Role of PARP Inhibitors in Ovarian Cancer

January 25th 2025

Emily M. Hinchcliff, MD, MPH, discusses future research directions regarding the role of PARP inhibitors for the treatment of patients with ovarian cancer.

Dr Alencar on the Rationale of Investigating BTK Degraders in CLL

January 24th 2025

Alvaro Alencar, MD, explains the rationale of a phase 1 trial investigating NX-5948, a BTK degrader, in chronic lymphocytic leukemia.

Dr Cruz-Correa on the FDA Approval of Tislelizumab Plus Chemotherapy for Metastatic Gastric/GEJ Cancer

January 24th 2025

Marcia Cruz-Correa, MD, PhD, AGAF, FASGE, discusses the FDA approval of tislelizumab plus chemotherapy for metastatic gastric or GEJ adenocarcinoma.

Dr Al Hallak on the Associated Risks of Cirrhosis and Portal Hypertension in HCC

January 24th 2025

Mohammed Najeeb Al Hallak, MD, MS, discusses treatment considerations for patients with HCC and the associated risks of cirrhosis and portal hypertension.

Dr Montero on Unmet Treatment Needs for HER2+ Metastatic Breast Cancer

January 23rd 2025

Alberto Montero, MD, MBA, CPHQ, discusses unmet treatment needs for patients with HER2-positive metastatic breast cancer.

Dr Jurczak on the Role of Nemtabrutinib in R/R Follicular Lymphoma Management

January 23rd 2025

Wojciech Jurczak, MD, discusses the role of nemtabrutinib in the management of relapsed or refractory follicular lymphoma.